--- title: "Caris Life Sciences (CAI) stock: news and investor profile" url: "https://aibio.space/companies/caris-life-sciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Caris Life Sciences, Inc. (NASDAQ: CAI), United States. The directory classifies it as Biotechnology." --- CAI Caris Life Sciences, Inc. NASDAQ · United States # Caris Life Sciences (CAI) news Debt Financing · 2026-04-02 ## [Caris Life Sciences takes $400,000,000 term loan from Blue Owl and Blackstone funds](https://aibio.space/news/caris-life-sciences-takes-400-000-000-term-loan-blue-owl-blackstone/) Caris Life Sciences took a $400,000,000 term loan from funds managed by Blue Owl and Blackstone to repay its 2023 credit agreement. The new deal also adds a $300,000,000 delayed draw facility for acquisitions, and the company already reported $796.3 million of cash at the end of 2025. ## Latest Caris Life Sciences news We have not published a story on Caris Life Sciences yet. When there is news, it will appear here. ## Caris Life Sciences at a glance - **Ticker**: CAI - **Listing**: NASDAQ - **Country**: United States - **Cash, Mar 31, 2026**: $822.2 million ### Related companies - [BioMarin Pharmaceutical](https://aibio.space/companies/biomarin-pharmaceutical/) NASDAQ: BMRN - [Curis](https://aibio.space/companies/curis/) NASDAQ: CRIS - [Kardigan](https://aibio.space/companies/kardigan/) NASDAQ: KARD - [Septerna](https://aibio.space/companies/septerna/) NASDAQ: SEPN - [Champions Oncology](https://aibio.space/companies/champions-oncology/) NASDAQ: CSBR - [Kura Oncology](https://aibio.space/companies/kura-oncology/) NASDAQ: KURA - [GRI Bio](https://aibio.space/companies/gri-bio/) NASDAQ: GRI - [PaxMedica](https://aibio.space/companies/paxmedica/) OTC: PXMD ### Also on NASDAQ - [BioVie](https://aibio.space/companies/biovie/) BIVI - [Neurogene](https://aibio.space/companies/neurogene/) NGNE - [Legend Biotech](https://aibio.space/companies/legend-biotech/) LEGN - [Vogenx](https://aibio.space/companies/vogenx/) VOGX - [Xencor](https://aibio.space/companies/xencor/) XNCR - [Conexeu Sciences](https://aibio.space/companies/conexeu-sciences/) CNXU ## What Caris Life Sciences does Caris Life Sciences describes itself as a next-generation AI TechBio company and precision medicine pioneer, founded in 2008. It develops and commercializes molecular profiling solutions and uses artificial intelligence and machine learning, with an initial focus on oncology. Its Molecular Intelligence portfolio includes the MI Profile platform for tissue-based whole exome and whole transcriptome sequencing, the Caris Assure platform for blood-based profiling, and the Precision Whole Genome platform, with a whole genome sequencing launch anticipated in 2026. The company says it has performed sequencing on over 1,000,000 cases and has built a multi-modal clinico-genomic dataset covering the cancer care continuum, including early detection, minimal residual disease tracking, therapy selection and treatment monitoring. Its Caris Discovery pillar uses the data and AI to find drug targets for antibody-directed therapies, small molecules, protein degradation and cell therapy. Named biopharma partners include Moderna, AbbVie, Xencor, Merck KGaA and Genentech. The company also works with the Caris Precision Oncology Alliance, a network of cancer centers and research consortia. | Product or program | What it is | Stage | |---|---|---| | MI Profile Platform | Tissue-based whole exome and whole transcriptome molecular profiling | | | Caris Assure Platform | Blood-based whole exome and whole transcriptome molecular profiling | | | Precision Whole Genome Platform | Blood and tissue whole genome sequencing | launch anticipated in 2026 | | Caris Discovery | AI-driven discovery of drug targets across several modalities | | Summarised from the company's [10-K filed Mar 3, 2026](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/cai-20251231.htm). ## Caris Life Sciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$812.0 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/) | [$412.3 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/) | | Research and development | [$101.6 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/) | [$113.9 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/) | | Net income (loss) | [-$68.1 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/) | [-$281.9 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/) | | Cash from operations | [$83.2 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/) | [-$245.2 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/) | | Cash and equivalents | [$796.3 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/) | [$64.0 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/) | | Short-term investments | [$2.3 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000055/) | [$2.2 million](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/) | Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $819.9 million, plus short-term investments of $2.3 million, $822.2 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Caris Life Sciences What is the ticker symbol of Caris Life Sciences? Caris Life Sciences, Inc. trades under the ticker CAI on NASDAQ. Where is Caris Life Sciences listed? Caris Life Sciences, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:49J; FWB:49J; GETTEX:49J; HAM:49J; HAN:49J; LS:A41A14; LSX:A41A14; MUN:49J; SWB:49J; TRADEGATE:49J; XETR:49J. What is the SEC CIK of Caris Life Sciences? The SEC Central Index Key (CIK) for Caris Life Sciences, Inc. is 2019410. Its filings are on SEC EDGAR. How many shares does Caris Life Sciences have outstanding? 282,595,186 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Caris Life Sciences listed under? Our directory records Caris Life Sciences, Inc. under United States. What does Caris Life Sciences do? Our directory classifies Caris Life Sciences, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Caris Life Sciences? The ISIN recorded for Caris Life Sciences, Inc. is US1421521071. Does aibio.space cover Caris Life Sciences? aibio.space lists Caris Life Sciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Caris Life Sciences incorporated? SEC records list its state or country of incorporation as TX. What does Caris Life Sciences develop? Caris Life Sciences describes itself as a next-generation AI TechBio company and precision medicine pioneer, founded in 2008. It develops and commercializes molecular profiling solutions and uses artificial intelligence and machine learning, with an initial focus on oncology. What is MI Profile Platform from Caris Life Sciences? MI Profile Platform: Tissue-based whole exome and whole transcriptome molecular profiling What is Caris Assure Platform from Caris Life Sciences? Caris Assure Platform: Blood-based whole exome and whole transcriptome molecular profiling What was Caris Life Sciences's revenue last year? $812.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Caris Life Sciences profitable? Caris Life Sciences, Inc. reported a net loss of $68.1 million for the fiscal year ended Dec 31, 2025, and generated $83.2 million of cash from operations, per its annual report to the SEC. How much does Caris Life Sciences spend on research and development? $101.6 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Caris Life Sciences Members talk about Caris Life Sciences (CAI). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Caris Life Sciences, newest first. Each line links the filing it comes from. 1. 2026-04-02 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03). [Source](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/cai-20260401.htm) 2. 2025-06-20 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/2019410/000110465925060762/tm2415719-25_424b4.htm) 3. 2025-05-23 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/2019410/000110465925052381/tm2415719-14_s1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CAI on TradingView](https://www.tradingview.com/symbols/NASDAQ-CAI/). ## SEC filings and registration - **SEC name**: Caris Life Sciences, Inc. - **CIK**: 2019410 - **Industry (SIC)**: Services-Medical Laboratories (8071) - **US tickers**: CAI (Nasdaq) - **State or country of incorporation**: TX - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 750 W JOHN CARPENTER FREEWAY, IRVING, TX, 75039 - **Phone**: (866) 771-8946 - **Shares outstanding**: 282,595,186 as of 2026-08-03 (10-Q filed 2026-08-05) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000061/cai-20260914.htm) filed 2026-09-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000055/cai-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000053/cai-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000046/cai-20260604.htm) filed 2026-06-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000044/cai-20260331.htm) filed 2026-05-08 - [8-K](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000040/cai-20260507.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000032/cai-20260423.htm) filed 2026-04-23 - [8-K](https://www.sec.gov/Archives/edgar/data/2019410/000201941026000019/cai-20260401.htm) filed 2026-04-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002019410), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Caris Life Sciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CAI, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Caris Life Sciences, Inc. - **Ticker**: CAI - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US1421521071 - **Other listed symbols**: DUS:49J; FWB:49J; GETTEX:49J; HAM:49J; HAN:49J; LS:A41A14; LSX:A41A14; MUN:49J; SWB:49J; TRADEGATE:49J; XETR:49J - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CAI/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/caris-life-sciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Caris Life Sciences (CAI) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/caris-life-sciences/